P
Pierre Dellamonica
Researcher at University of Nice Sophia Antipolis
Publications - 290
Citations - 8057
Pierre Dellamonica is an academic researcher from University of Nice Sophia Antipolis. The author has contributed to research in topics: Viral load & Population. The author has an hindex of 44, co-authored 289 publications receiving 7740 citations.
Papers
More filters
Journal ArticleDOI
Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial
Jacques Durant,P. H. Clevenbergh,Philippe Halfon,P. Delgiudice,S. Porsin,P. Simonet,N Montagne,Charles A. Boucher,J. M. Schapiro,Pierre Dellamonica +9 more
TL;DR: Genotypic-resistance testing is found to have a significant benefit on the virological response when choosing a therapeutic alternative for HIV-1-infected patients in whom combination therapy was not successful.
Journal ArticleDOI
HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population.
Charlotte Lewden,Geneviève Chêne,Philippe Morlat,François Raffi,Michel Dupon,Pierre Dellamonica,Jean-Luc Pellegrin,Christine Katlama,François Dabis,Catherine Leport +9 more
TL;DR: In this paper, the authors compared mortality rates in combination antiretroviral therapy (cART)-treated HIV-infected adults with mortality in the general population according to the level of CD4 cell count reached and the duration of exposure to cART.
Journal ArticleDOI
Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération National des Centres de Lutte contre le SIDA.
Yves Mouton,Serge Alfandari,Michel Valette,François Cartier,Pierre Dellamonica,Guy Humbert,Jean Marie Lang,Patrice Massip,Denis Mechali,Pascale Leclercq,Jacques Modaï,Henri Portier +11 more
TL;DR: This study supports the extensive use of HAART in HIV-infected patients and shows a clear benefit to early HAART with a drop in hospitalization days, new AIDS cases, and deaths.
Journal ArticleDOI
Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.
Jacques Durant,P. Clevenbergh,Rodolphe Garraffo,Philippe Halfon,S Icard,P. del Giudice,N Montagne,Jonathan M. Schapiro,Pierre Dellamonica +8 more
TL;DR: Multiple parameters determine the response to antiretroviral therapy and causes other than the development of drug resistance should be considered in the setting of therapeutic failure.
Journal ArticleDOI
A Randomized Trial of Three Maintenance Regimens Given after Three Months of Induction Therapy with Zidovudine, Lamivudine, and Indinavir in Previously Untreated HIV-1–Infected Patients
Gilles Pialoux,François Raffi,Françoise Brun-Vézinet,Vincent Meiffrédy,Philippe Flandre,J. A. Gastaut,Pierre Dellamonica,Patrick Yeni,Jean-François Delfraissy,Jean-Pierre Aboulker +9 more
TL;DR: In HIV-1-infected adults not previously treated with antiretroviral drugs whose plasma HIV- 1 RNA levels fell below 500 copies per milliliter after three months of induction therapy with zidovudine, lamivUDine, and indinavir, two-drug maintenance therapy was less effective in sustaining a reduced viral load than continued three-drug therapy.